Venlafaxine in Obsessive-compulsive Disorder
The DOI matches its Crossref record.
Abstract
In a contribution to the January 1995 issue of the Archives comparing the efficacy and tolerability of clomipramine, fluoxetine, fluvoxamine, and sertraline, Greist et al,1using a method of meta-analysis, found all 4 agents to be effective in the treatment of patients who have obsessive-compulsive disorder (OCD). Whereas all 4 are serotonin-transport inhibitors, clomipramine, with its noradrenergic transport—inhibition component, most notably showed an efficacy advantage. With regard to this finding, Greist et al stated, "It seems that something may be missing in fluoxetine, fluvoxamine, and sertraline that clomipramine contains." They posed the question, "Will agents such as... venlafaxine hydrochloride, which have selective and potent serotonin and noradrenergic transport inhibition and a better side-effect profile than clomipramine, work well in treating OCD?" I wish to respond by reporting our limited experience with venlafaxine therapy in such patients. Research that we have conducted suggests that the preliminary answer to this
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Katzman, M. A., Bleau, P., Blier, P., Chokka, P., Kjernisted, K., Van Ameringen, M., & the Canadian Anxiety Guidelines Initiative Group on behalf of the Anxiety Disorders Association of Canada/Association Canadienne des troubles anxieux and McGill University (2014) · BMC Psychiatry · doi:10.1186/1471-244x-14-s1-s1 · Cited by 1,090
Bandelow, B., Zohar, J., Hollander, E., Kasper, S., Möller, H.-J., WFSBP TASK FORCE ON TREATMENT GUIDE, Bandelow, B., Zohar, J., Hollander, E., Kasper, S., et al. (2008) · The World Journal of Biological Psychiatry · doi:10.1080/15622970802465807 · Cited by 854
Evidence-based pharmacotherapy of obsessive-compulsive disorder
Fineberg, N. A., Brown, A., Reghunandanan, S., & Pampaloni, I. (2012) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145711001829 · Cited by 336
Pharmacotherapy of Obsessive-compulsive Disorder and Obsessive-Compulsive Spectrum Disorders
Denys, D. (2006) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2006.02.013 · Cited by 213
A Double Blind Comparison of Venlafaxine and Paroxetine in Obsessive-Compulsive Disorder
Denys, D., van der Wee, N., van Megen, H. J. G. M., & Westenberg, H. G. M. (2003) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000095342.32154.54 · Cited by 151
“As mentioned earlier, the lack of improvement in the latter study was attributed to an inadequate duration of treatment (8 weeks) and to an inadequate dose level (a maximum of 225 mg/d).(17) In the present study, however, venlafaxine was found to be efficacious at doses of 150 mg/d.”
BackgroundInfluential
Metadata
- Authors
- Yaryura-Tobias, J. A.
- Venue
- Archives of General Psychiatry
- Publisher
- American Medical Association (AMA)
- Published
- 1996-07-01
- Volume
- 53
- Issue
- 7
- Pages
- 653
- ISSN
- 0003-990X (ISSN-L)
- OpenAlex
- W2089304863
- Cited by
- 53
- References
- 0
- FWCI
- 2.10
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Venlafaxine in Obsessive-compulsive Disorder. https://app.cochat.ai/papers/10.1001/archpsyc.1996.01830070103016
- The paper
- Yaryura-Tobias, J. A. (1996). Venlafaxine in Obsessive-compulsive Disorder. Archives of General Psychiatry. https://doi.org/10.1001/archpsyc.1996.01830070103016
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.